[非小细胞肺癌术后辅助治疗的进展]
[Advance of postoperative adjuvant therapy in non-small cell lung cancer].
作者信息
Han Na, Lu Hongyang
机构信息
Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), Hangzhou 310022, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2014 Jun 20;17(6):501-5. doi: 10.3779/j.issn.1009-3419.2014.06.12.
Abstract
Lung cancer including non-small cell lung cancer (NSCLC) and SCLC is the most commonly diagnosed cancer and leading cause of cancer-related death worldwide. This review focuses on progress of the effect, indications, regimens and the related biological markers of postoperative adjuvant chemotherapy in NSCLC.
摘要
肺癌包括非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC），是全球最常被诊断出的癌症，也是癌症相关死亡的主要原因。本综述聚焦于非小细胞肺癌术后辅助化疗在疗效、适应证、治疗方案及相关生物标志物方面的进展。
相似文献
1
[Advance of postoperative adjuvant therapy in non-small cell lung cancer].[非小细胞肺癌术后辅助治疗的进展]
Zhongguo Fei Ai Za Zhi. 2014 Jun 20;17(6):501-5. doi: 10.3779/j.issn.1009-3419.2014.06.12.
2
[The role of adjuvant chemotherapy in operable non-small cell lung cancer].[辅助化疗在可切除非小细胞肺癌中的作用]
Zhongguo Fei Ai Za Zhi. 2011 Mar;14(3):281-5. doi: 10.3779/j.issn.1009-3419.2011.03.15.
3
[Progress of Postoperative Adjuvant Chemotherapy in Stage I Non-small Cell Lung Cancer].[Ⅰ期非小细胞肺癌术后辅助化疗的研究进展]
Zhongguo Fei Ai Za Zhi. 2015 Jun;18(6):374-80. doi: 10.3779/j.issn.1009-3419.2015.06.08.
4
Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.拓扑异构酶 II ɑ 表达与非小细胞肺癌术后辅助化疗获益。
BMC Cancer. 2010 Nov 10;10:621. doi: 10.1186/1471-2407-10-621.
5
Chemotherapy: Effectiveness of adjuvant chemotherapy for resected NSCLC.化疗：辅助化疗对可切除非小细胞肺癌的疗效。
Nat Rev Clin Oncol. 2010 Nov;7(11):613-4. doi: 10.1038/nrclinonc.2010.165.
6
[Bronchial cancer--adjuvant chemotherapy].[支气管癌——辅助化疗]
Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir. 1990:89-94.
7
Adjuvant chemotherapy in non-small cell lung cancer (NSCLC).非小细胞肺癌的辅助化疗
Ann Oncol. 2007 Jul;18 Suppl 9:ix143-6. doi: 10.1093/annonc/mdm309.
8
Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review.完全切除的非小细胞肺癌术后辅助全身治疗：一项系统评价
Clin Lung Cancer. 2017 May;18(3):259-273.e8. doi: 10.1016/j.cllc.2016.07.002. Epub 2016 Jul 12.
9
Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.完全切除的非小细胞肺癌患者辅助化疗的转诊模式。
J Thorac Oncol. 2007 Jan;2(1):39-43. doi: 10.1097/JTO.0b013e31802baff6.
10
Non-small-cell lung cancer--stalemate or progress?非小细胞肺癌——僵局还是进展？
N Engl J Med. 2000 Oct 26;343(17):1261-2. doi: 10.1056/NEJM200010263431710.
本文引用的文献
1
Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.培美曲塞联合卡铂辅助化疗联合或不联合吉非替尼用于切除的伴有EGFR突变的IIIA-N2期非小细胞肺癌：一项随机II期研究。
Ann Surg Oncol. 2014 Jun;21(6):2091-6. doi: 10.1245/s10434-014-3586-9. Epub 2014 Mar 1.
2
Lymphovascular invasion as a prognostic indicator in stage I non-small cell lung cancer: a systematic review and meta-analysis.脉管侵犯作为 I 期非小细胞肺癌的预后指标：系统评价和荟萃分析。
Ann Thorac Surg. 2014 Mar;97(3):965-71. doi: 10.1016/j.athoracsur.2013.11.002. Epub 2014 Jan 11.
3
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.非小细胞肺癌中 ERCC1 异构体表达与 DNA 修复。
N Engl J Med. 2013 Mar 21;368(12):1101-10. doi: 10.1056/NEJMoa1214271.
4
Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.随机 2 期临床试验：在早期 NSCLC 辅助化疗中用顺铂和培美曲塞替代顺铂和长春瑞滨进行优化：TREAT 研究。
Ann Oncol. 2013 Apr;24(4):986-92. doi: 10.1093/annonc/mds578. Epub 2012 Nov 15.
5
ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.ERCC1 表达作为非小细胞肺癌患者的预后和预测因素的荟萃分析。
Mol Biol Rep. 2012 Jun;39(6):6933-42. doi: 10.1007/s11033-012-1520-4.
6
7
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.2008 年全球癌症负担估计值：GLOBOCAN 2008。
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
8
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.采用自动化定量原位分析技术检测 ERCC1 和 RRM1 在国际辅助性肺试验中的表达。
Am J Pathol. 2011 Jan;178(1):69-78. doi: 10.1016/j.ajpath.2010.11.029. Epub 2010 Dec 23.
9
10
MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer.错配修复蛋白 2 与肺癌辅助化疗的长期获益。
Clin Cancer Res. 2010 Feb 15;16(4):1206-15. doi: 10.1158/1078-0432.CCR-09-2204. Epub 2010 Feb 9.
Zotero 插件